These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

247 related items for PubMed ID: 23439261

  • 1. The liver diseases of lipodystrophy: the long-term effect of leptin treatment.
    Safar Zadeh E, Lungu AO, Cochran EK, Brown RJ, Ghany MG, Heller T, Kleiner DE, Gorden P.
    J Hepatol; 2013 Jul; 59(1):131-7. PubMed ID: 23439261
    [Abstract] [Full Text] [Related]

  • 2. Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy.
    Javor ED, Ghany MG, Cochran EK, Oral EA, DePaoli AM, Premkumar A, Kleiner DE, Gorden P.
    Hepatology; 2005 Apr; 41(4):753-60. PubMed ID: 15791619
    [Abstract] [Full Text] [Related]

  • 3. Effects of Metreleptin in Pediatric Patients With Lipodystrophy.
    Brown RJ, Meehan CA, Cochran E, Rother KI, Kleiner DE, Walter M, Gorden P.
    J Clin Endocrinol Metab; 2017 May 01; 102(5):1511-1519. PubMed ID: 28324110
    [Abstract] [Full Text] [Related]

  • 4. Type 1 diabetes associated with acquired generalized lipodystrophy and insulin resistance: the effect of long-term leptin therapy.
    Park JY, Chong AY, Cochran EK, Kleiner DE, Haller MJ, Schatz DA, Gorden P.
    J Clin Endocrinol Metab; 2008 Jan 01; 93(1):26-31. PubMed ID: 17940115
    [Abstract] [Full Text] [Related]

  • 5. Clinical effects of long-term metreleptin treatment in patients with lipodystrophy.
    Chan JL, Lutz K, Cochran E, Huang W, Peters Y, Weyer C, Gorden P.
    Endocr Pract; 2011 Jan 01; 17(6):922-32. PubMed ID: 22068254
    [Abstract] [Full Text] [Related]

  • 6. Leptin in the treatment of lipodystrophy-associated nonalcoholic fatty liver disease: are we there already?
    Machado MV, Cortez-Pinto H.
    Expert Rev Gastroenterol Hepatol; 2013 Aug 01; 7(6):513-5. PubMed ID: 23985000
    [Abstract] [Full Text] [Related]

  • 7. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy.
    Petersen KF, Oral EA, Dufour S, Befroy D, Ariyan C, Yu C, Cline GW, DePaoli AM, Taylor SI, Gorden P, Shulman GI.
    J Clin Invest; 2002 May 01; 109(10):1345-50. PubMed ID: 12021250
    [Abstract] [Full Text] [Related]

  • 8. Metreleptin therapy for nonalcoholic steatohepatitis: Open-label therapy interventions in two different clinical settings.
    Akinci B, Subauste A, Ajluni N, Esfandiari NH, Meral R, Neidert AH, Eraslan A, Hench R, Rus D, McKenna B, Hussain HK, Chenevert TL, Tayeh MK, Rupani AR, Innis JW, Mantzoros CS, Conjeevaram HS, Burant CL, Oral EA.
    Med; 2021 Jul 09; 2(7):814-835. PubMed ID: 35291351
    [Abstract] [Full Text] [Related]

  • 9. Leptin decreases de novo lipogenesis in patients with lipodystrophy.
    Baykal AP, Parks EJ, Shamburek R, Syed-Abdul MM, Chacko S, Cochran E, Startzell M, Gharib AM, Ouwerkerk R, Abd-Elmoniem KZ, Walter PJ, Walter M, Muniyappa R, Chung ST, Brown RJ.
    JCI Insight; 2020 Jul 23; 5(14):. PubMed ID: 32573497
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy.
    Ebihara K, Kusakabe T, Hirata M, Masuzaki H, Miyanaga F, Kobayashi N, Tanaka T, Chusho H, Miyazawa T, Hayashi T, Hosoda K, Ogawa Y, DePaoli AM, Fukushima M, Nakao K.
    J Clin Endocrinol Metab; 2007 Feb 23; 92(2):532-41. PubMed ID: 17118991
    [Abstract] [Full Text] [Related]

  • 11. Recombinant human leptin treatment in genetic lipodystrophic syndromes: the long-term Spanish experience.
    Araujo-Vilar D, Sánchez-Iglesias S, Guillín-Amarelle C, Castro A, Lage M, Pazos M, Rial JM, Blasco J, Guillén-Navarro E, Domingo-Jiménez R, del Campo MR, González-Méndez B, Casanueva FF.
    Endocrine; 2015 May 23; 49(1):139-47. PubMed ID: 25367549
    [Abstract] [Full Text] [Related]

  • 12. Hepatic steatosis in human immunodeficiency virus: a prospective study in patients without viral hepatitis, diabetes, or alcohol abuse.
    Sterling RK, Smith PG, Brunt EM.
    J Clin Gastroenterol; 2013 Feb 23; 47(2):182-7. PubMed ID: 23059409
    [Abstract] [Full Text] [Related]

  • 13. Long-term efficacy of leptin replacement in patients with generalized lipodystrophy.
    Javor ED, Cochran EK, Musso C, Young JR, Depaoli AM, Gorden P.
    Diabetes; 2005 Jul 23; 54(7):1994-2002. PubMed ID: 15983199
    [Abstract] [Full Text] [Related]

  • 14. A Report of Three Cases With Acquired Generalized Lipodystrophy With Distinct Autoimmune Conditions Treated With Metreleptin.
    Lebastchi J, Ajluni N, Neidert A, Oral EA.
    J Clin Endocrinol Metab; 2015 Nov 23; 100(11):3967-70. PubMed ID: 26390101
    [Abstract] [Full Text] [Related]

  • 15. Fatty liver in lipodystrophy: A review with a focus on therapeutic perspectives of adiponectin and/or leptin replacement.
    Polyzos SA, Perakakis N, Mantzoros CS.
    Metabolism; 2019 Jul 23; 96():66-82. PubMed ID: 31071311
    [Abstract] [Full Text] [Related]

  • 16. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver.
    Pais R, Charlotte F, Fedchuk L, Bedossa P, Lebray P, Poynard T, Ratziu V, LIDO Study Group.
    J Hepatol; 2013 Sep 23; 59(3):550-6. PubMed ID: 23665288
    [Abstract] [Full Text] [Related]

  • 17. Leptin Attenuates Cardiac Hypertrophy in Patients With Generalized Lipodystrophy.
    Nguyen ML, Sachdev V, Burklow TR, Li W, Startzell M, Auh S, Brown RJ.
    J Clin Endocrinol Metab; 2021 Oct 21; 106(11):e4327-e4339. PubMed ID: 34223895
    [Abstract] [Full Text] [Related]

  • 18. Biochemical and histological characterisation of an experimental rodent model of non-alcoholic steatohepatitis - Effects of a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist and a glucagon-like peptide-1 analogue.
    Daniels SJ, Leeming DJ, Detlefsen S, Bruun MF, Hjuler ST, Henriksen K, Hein P, Karsdal MA, Brockbank S, Cruwys S.
    Biomed Pharmacother; 2019 Mar 21; 111():926-933. PubMed ID: 30841472
    [Abstract] [Full Text] [Related]

  • 19. [Therapy resistant diabetes mellitus and lipodystrophy: leptin therapy leads to improvement].
    Jazet IM, Jonker JT, Wijngaarden MA, Lamb H, Smelt AH.
    Ned Tijdschr Geneeskd; 2013 Mar 21; 157(4):A5482. PubMed ID: 23343738
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.